【氣喘】《Enveda》宣布原治療異位性皮膚炎「ENV-294」進行第二個適應症氣喘的測試

 【氣喘】《Enveda》宣布原治療異位性皮膚炎「ENV-294」進行第二個適應症氣喘的測試

 文章出處  

Businesswire 

 

 原文標題  

Enveda Expands into Asthma with First-in-Class Lead Asset ENV-294 and Assembles World-Class Advisory Board 

 

 Twitter  

https://x.com/aimedadviser/status/1888508170311803274 

 

 文章序號  

7260 

 

智醫科學－AI醫療技術、應用與市場動態

Copyright ©2025 智醫科學 MEDai.tw All rights reserved.

The content of this site is intended for healthcare and medical professionals.